

EGFR INHIBITORS

Beyond the First Decade

Generic Name	Brand Name	FDA Approved for the Treatment of Pancreatic Cancer	FDA Approved for the Treatment of SCCHN	FDA Approved for the Treatment of NSCLC	FDA Approved for the Treatment of Breast Cancer	FDA Approved for the Treatment of Colorectal Cancer	FDA Approved for the Treatment of Other Cancers	FDA Approved for Other Indications
Ammonium lactate 12% cream	Lac-Hydrin, AmLactin							√
Bevacizumab	Avastin			√	√	√		
Capecitabine	Xeloda				√	√		√
Carboplatin	various						√	
Cetuximab	Erbitux		√			√		
Cisplatin	various						√	
Clindamycin gel	various							√
Diphenhydramine	Benadryl							√
Erlotinib	Tarceva	√		√				
Fluorometholone	various							√
Fluorouracil	various	√			√	√	√	
Flurandrenolide	Cordran							√
Fluticasone propionate 0.5%	Cutivate							√
Gefitinib	Iressa			√				
Gemcitabine	Gemzar	√		√	√		√	
Hydroxyzine	Atarax							√
Irinotecan	Camptosar					√		
Lapatinib	Tykerb				√			
Lidocaine	various							√
Methylprednisolone	various							√
Metronidazole	various							√
Mometasone furoate	various							√
Mupirocin	Bactroban							√
Oxaliplatin	Eloxatin					√		
Paclitaxel	various			√	√		√	
Panitumumab	Vectibix					√		
Pimecrolimus	Elidel							√
Pregabalin	Lyrica							√
Tacrolimus	Protopic							√
Tazarotene topical	Tazorac							√

FDA = US Food and Drug Administration; NSCLC = non-small cell lung cancer; SCCHN = squamous cell carcinoma of the head and neck. Adapted from *Drug Facts and Comparisons*. St Louis, Mo: Facts & Comparisons; 2008. Agents may be approved for use in combination.